Information Provided By:
Fly News Breaks for March 25, 2015
MDVN
Mar 25, 2015 | 09:06 EDT
William Blair raised its price target for Medivation shares to $144 saying yesterday's data set demonstrated clear superiority of Xtandi to Casodex across all endpoints in metastatic prostate cancer patients who have progressed on Lupron. The firm believes the "slightly worse safety profile" should not hinder uptake and keeps an Outperform rating on the stock.
News For MDVN From the Last 2 Days
There are no results for your query MDVN